1-20 of 30
Patrick M. Reagan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Mazyar Shadman, Marcelo Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle, Peiman Hematti, Jonathon B. Cohen, Farhad Khimani, Siddhartha Ganguly, Reid W. Merryman, Jean A. Yared, Frederick L. Locke, Nausheen Ahmed, Pashna N. Munshi, Amer Beitinjaneh, Patrick M. Reagan, Alex F. Herrera, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani
Journal: Blood
Blood (2022) 139 (9): 1330–1339.
DOI: https://doi.org/10.1182/blood.2021013289
Published: 2022
Includes: Supplemental data
Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron Jacobson, Miguel-Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom Van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin
Journal: Blood
Blood (2021) 138 (Supplement 1): 2.
DOI: https://doi.org/10.1182/blood-2021-148039
Published: 2021
Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Caron Jacobson, Frederick L. Locke, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick Stiff, Ian W. Flinn, Umar Farooq, Andre H. Goy, Javier Muñoz, Tanya Siddiqi, Rhine R. Shen, Adrian Bot, Jinghui Dong, Kanwarjit Singh, Clare Spooner, Roshan Karalliyadda, Jenny J. Kim, Yan Zheng, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1764.
DOI: https://doi.org/10.1182/blood-2021-148078
Published: 2021
Journal Articles

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr
Journal: Blood
Blood (2021) 138 (Supplement 1): 2640.
DOI: https://doi.org/10.1182/blood-2021-145490
Published: 2021
Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1418.
DOI: https://doi.org/10.1182/blood-2021-147567
Published: 2021
Journal Articles

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, Michael D. Jain, Loretta Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, Andre H. Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Matthew L. Ulrickson, Jason R. Westin, Julio C. Chavez, Miriam T. Jacobs, N Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Saurabh Dahiya, Matthew A. Lunning
Journal: Blood
Blood (2021) 138 (Supplement 1): 3826.
DOI: https://doi.org/10.1182/blood-2021-147488
Published: 2021
Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Clinical Trials & Observations Brief Report
Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, Richard E. Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (12): 1081–1085.
DOI: https://doi.org/10.1182/blood.2021010930
Published: 2021
Includes: Supplemental data
Journal Articles

Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)

Caron Jacobson, MD MMSc, Frederick L. Locke, MD, Armin Ghobadi, MD, David B. Miklos, MD PhD, Lazaros J. Lekakis, MD, Olalekan O. Oluwole, MBBS, MPH, Yi Lin, MD PhD, Ira Braunschweig, MD, Brian T. Hill, MD, John M. Timmerman, MD, Abhinav Deol, MD, Patrick M. Reagan, MD, Patrick J. Stiff, MD, Ian W. Flinn, MD PhD, Umar Farooq, MD, Andre H. Goy, MD, Peter A. McSweeney, MD, Javier Munoz, MD, Tanya Siddiqi, MD, John M. Rossi, MS, Adrian Bot, MD PhD, Lianqing Zheng, PhD, Remus Vezan, MD PhD, Zahid Bashir, MBBS, Jenny J. Kim, MD MS, Rong Chu, PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
DOI: https://doi.org/10.1182/blood-2020-134362
Published: 2020
Journal Articles

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD, Marie José Kersten, MD PhD, Noel Milpied, Henry C.H. Fung, MD, Max S. Topp, MD, Roch Houot, MD PhD, Amer Beitinjaneh, MD MPH, MSc, Weimin Peng, PhD, Lianqing Zheng, PhD, John M. Rossi, MS, Swaminathan Murugappan, MD PhD, Ioana Kloos, MD, Patrick M. Reagan, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
DOI: https://doi.org/10.1182/blood-2020-136382
Published: 2020
Journal Articles

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael Wang, MD, John M. Rossi, MS, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Patrick M. Reagan, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Weimin Peng, PhD, Lianqing Zheng, PhD, Xiang Fang, PhD, Allen Xue, PhD, Ioana Kloos, MD, Adrian Bot, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29.
DOI: https://doi.org/10.1182/blood-2020-136831
Published: 2020
Journal Articles

Arrhythmia Burden in Patients with Indolent Lymphoma

Mujtaba Soniwala, DO, Saadia Sherazi, MBBS, MS, Susan Schleede, MS, Scott McNitt, MS, Tina Faugh, Jeremiah Moore, PharmD, Justin Foster, PharmD, Clive S. Zent, MD, Paul M. Barr, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD MSSc, Eugene Storozynsky, MDPhD, Ilan Goldenberg, MD, Carla Casulo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
DOI: https://doi.org/10.1182/blood-2020-140053
Published: 2020
Journal Articles

A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Craig A. Portell, MD, Carla Casulo, MD, Andrea M. Baran, MS, Allison Magnuson, DO, Paul M. Barr, MD, Yelena Lerman, PhD, Krista N French, Jonathan W. Friedberg, MD MSSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
DOI: https://doi.org/10.1182/blood-2020-140384
Published: 2020
Journal Articles

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Miriam T. Jacobs, MD, Michael D. Jain, MD PhD, Jay Y. Spiegel, MDFRCPC, Loretta J. Nastoupil, MD MSc, Yibo Li, MD, Gao Feng, Matthew A. Lunning, DO, FACP, Lazaros J Lekakis, MD, Saurabh Dahiya, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Charalambos Andreadis, MD MSCE, Javier Munoz, MD, Julio Chavez, N. Nora Bennani, MD, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Sattva S Neelapu, MD, Armin Ghobadi, MD, Frederick L. Locke, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1583.
DOI: https://doi.org/10.1182/blood-2019-131168
Published: 2019
Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Michael L. Wang, MD, Javier Munoz, MD, Andre Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD MMSc, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, MD, Samantha Jaglowski, MDMPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD DSc, Marie Jose Kersten, MD PhD, Weimin Peng, MS, Lianqing Zheng, PhD, John M. Rossi, MS, Rajul K. Jain, MD, Arati V. Rao, MD, Patrick M Reagan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 754.
DOI: https://doi.org/10.1182/blood-2019-126064
Published: 2019
Journal Articles

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium

N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD MSc, Michael D. Jain, MD PhD, Julio C. Chavez, MD, Amanda F Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Khoan Vu, MD, Charalambos Andreadis, MD, Javier Munoz, MD MS, FACP, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Frederick L. Locke, MD, Sattva S Neelapu, MD, Yi Lin, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 763.
DOI: https://doi.org/10.1182/blood-2019-129097
Published: 2019
Journal Articles

Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Michael D. Jain, MD PhD, Miriam T. Jacobs, MD, Loretta J. Nastoupil, MD MSc, Jay Y. Spiegel, MDFRCPC, Gao Feng, Yi Lin, MD PhD, Matthew A. Lunning, DO, FACP, Saurabh Dahiya, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Andre Goy, MD, Brian T. Hill, MD, Javier Munoz, MD, Julio Chavez, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Sattva S Neelapu, MD, N. Nora Bennani, MD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Armin Ghobadi, MD, Frederick L. Locke, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 245.
DOI: https://doi.org/10.1182/blood-2019-129624
Published: 2019
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
DOI: https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4095.
DOI: https://doi.org/10.1182/blood-2019-125792
Published: 2019
Journal Articles

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Sattva S Neelapu, MD, John M. Rossi, MS, Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Patrick M Reagan, MD, Scott J Rodig, MD PhD, Lazaros J. Lekakis, MD, Ian W. Flinn, MD PhD, Lianqing Zheng, PhD, Francesca Milletti, PhD, Edmund Chang, PhD, Allen Xue, PhD, Vicki Plaks, PhD, Jenny J. Kim, MD MS, Adrian Bot, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 203.
DOI: https://doi.org/10.1182/blood-2019-126218
Published: 2019
Journal Articles

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Loretta J. Nastoupil, MD, Michael D. Jain, MDPhD, Jay Y. Spiegel, MD, Armin Ghobadi, MD, Yi Lin, MD PhD, Saurabh Dahiya, MD, Matthew A. Lunning, DO, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD PhD, Charalambos Andreadis, MD, Javier Munoz, MD, Jason R. Westin, MD, Julio C. Chavez, MD, Amanda F Cashen, MD, Nora N Bennani, MD, Aaron P. Rapoport, MD, Julie M. Vose, MDMBA, David B. Miklos, MD PhD, Sattva S. Neelapu, MD, Frederick L. Locke, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 91.
DOI: https://doi.org/10.1182/blood-2018-99-114152
Published: 2018